A couple of recent controversies in the field of angiogenesis have fascinated scientists and clinicians alike, namely:
- Does VEGF inhibition lead to more aggressive tumours?
- What drives metastases and invasion?
- What is the role of tumour hypoxia in this process?
Data was originally presented in glioblastoma by Rubenstein et al., (2000), showing that anti-VEGF antibody treatment prolonged survival, but resulted in increased vascularity caused quite a stir. Several other groups subsequently demonstrated in preclinical models that VEGF signaling shrinks tumours, but also results in increased invasion and metastases (see Casanovas et al., (2005), Ebos et al., (2009), Paez-Ribes et al., (2009), for examples).